{"id":389100,"date":"2023-12-22T00:00:00","date_gmt":"2023-12-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0016-2023-biopharma-acute-myeloid-leukemia-disease-landscape-forecast-g7-2023\/"},"modified":"2026-05-25T11:14:36","modified_gmt":"2026-05-25T11:14:36","slug":"dlsfon0016-2023-biopharma-acute-myeloid-leukemia-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0016-2023-biopharma-acute-myeloid-leukemia-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Acute Myeloid Leukemia | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, it has had a relatively poor prognosis, including low five-year overall survival rates. Chemotherapy backbones have long dominated the treatment of AML, but recent drug approvals suggest a shift toward targeted agents. The approval of Rigel Pharmaceuticals\u2019 Rezlidhia, a potent inhibitor of IDH1, underlines this trend. Rezlidhia joins Tibsovo (ivosidenib) in treating the <em>IDH1<\/em>-mutated relapsed\/refractory AML population. In addition, the early- and late-phase AML pipelines are active and span several drug classes, including kinase inhibitors, radio-immunotherapeutics, menin inhibitors, therapeutic vaccines, antibody-drug conjugates, and CAR T-cell therapies. With the uptake of new therapies and label expansions, we expect the AML therapy market to grow substantially over the 10-year forecast period.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>What is the size of the clinically and commercially relevant drug-treatable AML population, and how will drug-treatment rates change over the 2022-2032 forecast period?<\/li>\n<li>What is the current treatment landscape for AML? What insights do interviewed experts provide?<\/li>\n<li>Which emerging therapies are the most promising for AML? Which drug-treatable subpopulations will they target?<\/li>\n<li>What factors are driving the growth of the AML therapy market, and how will this market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancements<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n<p><strong>Geographies<\/strong>: United States, EU5, Japan.<\/p>\n<p><strong>Primary research<\/strong>: 19 country-specific interviews with thought-leading hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology<\/strong>: Diagnosed incidence cases of AML by country, clinically, and market-relevant drug-treatable populations.<\/p>\n<p><strong>Forecast<\/strong>: 10-year, annualized, drug-level, and regimen-level sales and patient share of key AML therapies through 2032, segmented by brands \/ generics \/ biosimilars and drug-treatable subpopulations.<\/p>\n<p><strong>Emerging therapies<\/strong>: Phase 2\/3: 9+ drugs; coverage of select early-phase products.<\/p>\n","protected":false},"template":"","class_list":["post-389100","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-myeloid-leukemia","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389100\/revisions"}],"predecessor-version":[{"id":576007,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389100\/revisions\/576007"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}